IOVA vs. TWST, RLAY, FATE, CBPO, NKTR, QGEN, RGEN, PCVX, RVMD, and EXEL
Should you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Twist Bioscience (TWST), Relay Therapeutics (RLAY), Fate Therapeutics (FATE), China Biologic Products (CBPO), Nektar Therapeutics (NKTR), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), and Exelixis (EXEL). These companies are all part of the "medical" sector.
Twist Bioscience (NASDAQ:TWST) and Iovance Biotherapeutics (NASDAQ:IOVA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.
Twist Bioscience has a net margin of -69.24% compared to Twist Bioscience's net margin of -23,615.70%. Iovance Biotherapeutics' return on equity of -31.61% beat Twist Bioscience's return on equity.
Twist Bioscience currently has a consensus target price of $42.50, indicating a potential upside of 1.43%. Iovance Biotherapeutics has a consensus target price of $24.64, indicating a potential upside of 177.44%. Given Twist Bioscience's higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Twist Bioscience.
Twist Bioscience has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
In the previous week, Iovance Biotherapeutics had 5 more articles in the media than Twist Bioscience. MarketBeat recorded 10 mentions for Iovance Biotherapeutics and 5 mentions for Twist Bioscience. Iovance Biotherapeutics' average media sentiment score of 1.21 beat Twist Bioscience's score of 0.69 indicating that Twist Bioscience is being referred to more favorably in the media.
Iovance Biotherapeutics received 471 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 74.57% of users gave Iovance Biotherapeutics an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
77.0% of Iovance Biotherapeutics shares are held by institutional investors. 3.9% of Twist Bioscience shares are held by company insiders. Comparatively, 10.4% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Twist Bioscience has higher revenue and earnings than Iovance Biotherapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Iovance Biotherapeutics beats Twist Bioscience on 10 of the 17 factors compared between the two stocks.
Get Iovance Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iovance Biotherapeutics Competitors List
Related Companies and Tools
